Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Progestin

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   43881   clinical trials with a EudraCT protocol, of which   7295   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    185 result(s) found for: Progestin. Displaying page 1 of 10.
    1  2  3  4  5  6  7  8  9  Next» Last»»
    EudraCT Number: 2022-002678-10 Sponsor Protocol Number: GF22002 Start Date*: 2023-03-07
    Sponsor Name:Ginefiv
    Full Title: Protocol with progestin-primed ovarian stimulation (PPOS) starting on day 5 versus protocol with progestin-primed ovarian stimulation (PPOS) in a conventional regimen from the start of the ovaria...
    Medical condition: Number of MII oocytes obtained in both groups
    Disease:
    Population Age: Adults Gender: Female
    Trial protocol: ES (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2017-004864-37 Sponsor Protocol Number: ASP-OP3-1 Start Date*: 2018-05-16
    Sponsor Name:Aspen Global Incorporated
    Full Title: A Multinational, Phase 3, Double-blind, Placebo-Controlled, Randomized Study to Assess the Efficacy and Safety of Ovestin in the Treatment of Symptoms of Vulvar and Vaginal Atrophy in Postmenopausa...
    Medical condition: Vulvovaginal atrophy associated with menopause
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004872 10047782 Vulvovaginal atrophy LLT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: BG (Prematurely Ended) PL (Completed)
    Trial results: View results
    EudraCT Number: 2004-000053-34 Sponsor Protocol Number: 0473081 Start Date*: 2004-07-28
    Sponsor Name:Orion Corporation, Orion Pharma, Orionintie,
    Full Title: Comparison of continuous combined estrogen-progestin regimen in alleviation of estrogen deficiency symptoms of postmenopausal women. A randomized, double-blind, fixed dose, multicentre phase IIIb ...
    Medical condition: Postmenopausal estrogen replacement regimen is the therapy of choice for the alleviation of climacteric symptoms. During the past few years, continuous-combined hormone replacement therapy (HRT) ...
    Disease: Version SOC Term Classification Code Term Level
    7.0 10027304 LLT
    Population Age: Adults Gender: Female
    Trial protocol: CZ (Completed)
    Trial results: View results
    EudraCT Number: 2014-001243-20 Sponsor Protocol Number: SYLVI030785 Start Date*: 2014-06-11
    Sponsor Name:Helsinki University Central Hospital
    Full Title: Syntethic vs. natural estrogen in combined oral contraception- effect on insulinsensitivity, inflammation, coagulation and endometrium. A comparison with a progestin-only preparation.
    Medical condition: Healthy women, contraception
    Disease: Version SOC Term Classification Code Term Level
    17.0 100000004865 10073728 Hormonal contraception LLT
    Population Age: Adults Gender: Female
    Trial protocol: FI (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2008-000634-53 Sponsor Protocol Number: AP23573-07-205(8669-007) Start Date*: 2008-11-07
    Sponsor Name:Merck Sharp & Dohme Corp.,
    Full Title: A randomized phase II trial of ridaforolimus (AP23573; MK-8669) compared to progestin or chemotherapy in female adult patients with advanced endometrial carcinoma
    Medical condition: advanced endometrial carcinoma
    Disease: Version SOC Term Classification Code Term Level
    14.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10014747 Endometrial carcinoma recurrent LLT
    14.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10014745 Endometrial carcinoma metastatic LLT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: GB (Completed) DE (Prematurely Ended) CZ (Completed) ES (Completed) IT (Completed) FR (Completed)
    Trial results: View results
    EudraCT Number: 2022-003049-37 Sponsor Protocol Number: CS-10459 Start Date*: 2022-11-23
    Sponsor Name:UZ Brussel
    Full Title: Luteal phase ovarian stimulation with Follitropin delta and dydrogesterone: a randomized cross over pilot trial
    Medical condition: Volutary women who wish to donate their oocytes
    Disease:
    Population Age: Adults Gender: Female
    Trial protocol: BE (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2014-001434-29 Sponsor Protocol Number: VX-EC-2-2013 Start Date*: 2015-01-13
    Sponsor Name:AS Kevelt
    Full Title: A Phase II Study of Sodium Cridanimod in Conjunction with Progestin Therapy in Patients with Progesterone Receptor Negative Recurrent or Persistent Endometrial Carcinoma.
    Medical condition: PrR negative papillary serous adenocarcinoma, endometroid type of endometrial carcinoma
    Disease: Version SOC Term Classification Code Term Level
    17.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10014743 Endometrial carcinoma LLT
    17.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10014747 Endometrial carcinoma recurrent LLT
    17.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10033700 Papillary serous endometrial carcinoma PT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: CZ (Completed) SK (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2009-017942-30 Sponsor Protocol Number: 0914M0622 Start Date*: 2010-06-15
    Sponsor Name:Shionogi USA, Inc.
    Full Title: An open-label safety study of S-888711 in adult subjects with relapsed persistent or chronic immune thrombocytopenia with or without prior splenectomy
    Medical condition: Relapsed persistent or chronic immune thrombocytopenia with or without prior splenectomy
    Disease: Version SOC Term Classification Code Term Level
    12.1 10066667 Chronic thrombocytopenia LLT
    12.1 10063129 Persisting thrombocytopenia LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Ongoing) GB (Prematurely Ended) DE (Prematurely Ended) HU (Completed) IT (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2012-002449-40 Sponsor Protocol Number: P057-00 Start Date*: 2012-10-12
    Sponsor Name:Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc.
    Full Title: A multicenter, randomized, partially blinded, placebo-controlled clinical trial to evaluate the effect on primary dysmenorrheal of vaginal rings with an average daily release of 700 μg nomegestrol...
    Medical condition: This study will investigate the use of 4 doses of combined contraceptives (a progestin with an estrogen) in a vaginal ring dosage form for the treatment of dysmenorrhea (menstrual cramping pain). A...
    Disease:
    Population Age: Adults Gender: Female
    Trial protocol: DE (Completed) NO (Completed) NL (Completed) BE (Completed) SE (Completed) PL (Completed) DK (Completed) ES (Completed)
    Trial results: View results
    EudraCT Number: 2006-006199-39 Sponsor Protocol Number: 310523 Start Date*: 2007-07-05
    Sponsor Name:Bayer AB, Bayer Schering Pharma
    Full Title: A double-blind, randomized, multi-center study to investigate the endometrial safety of a continuous, combined, oral estrogen/progestin preparation (0.5 mg 17b-estradiol [E2] / 0.25 mg drospirenone...
    Medical condition: Women suffering from postmenopausal symptoms
    Disease: Version SOC Term Classification Code Term Level
    9.1 10050903 Postmenopausal symptoms LLT
    Population Age: Adults Gender: Female
    Trial protocol: DK (Completed) AT (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2015-004184-36 Sponsor Protocol Number: UKER-AN-HS-01 Start Date*: 2016-01-05
    Sponsor Name:Universitätsklinikum Erlangen
    Full Title: Prospective, randomised, double-blind, placebo-controlled, single centre phase IIa clinical trial to investigate the safety and tolerability as well as the impact of a substitution of sexual hormon...
    Medical condition: Substitution of sexual hormones in adult females with anorexia nervosa
    Disease: Version SOC Term Classification Code Term Level
    18.1 100000004865 10063915 Substitution therapy LLT
    Population Age: Adults Gender: Female
    Trial protocol: DE (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2006-005460-30 Sponsor Protocol Number: 2004.363/18 Start Date*: 2007-05-22
    Sponsor Name:OSPEDALI CIVILI DI LIONE
    Full Title: POPART’MUS Prevention of Post Partum Relapses with Progestin and Estradiol in Multiple sclerosis
    Medical condition: Multiple Sclerosis
    Disease: Version SOC Term Classification Code Term Level
    9.1 10028245 Multiple sclerosis LLT
    Population Age: Adults Gender: Female
    Trial protocol: IT (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2004-004434-14 Sponsor Protocol Number: FFR103184 Start Date*: 2005-04-05
    Sponsor Name:GlaxoSmithKline Research & Development Ltd
    Full Title: A randomized, double-blind, placebo-controlled, parallel group, multicenter two week study to evaluate the efficacy and safety of once-daily, intranasal administration of GW685698X aqueous nasal sp...
    Medical condition: Seasonal allergic rhinitis (SAR)
    Disease:
    Population Age: Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: SE (Completed) LT (Completed) EE (Completed) LV (Completed)
    Trial results: View results
    EudraCT Number: 2021-002467-22 Sponsor Protocol Number: FSD-PSE-2021-09 Start Date*: 2021-07-02
    Sponsor Name:Fundacion Santiago Dexeus Font
    Full Title: Dual Trigger vs. GnRH-a Trigger for Elective Fertility Preservation. A randomized controlled trial.
    Medical condition: This study is a randomized controlled, superiority trial comparing the number of MII oocytes following final follicle maturation with dual trigger (250 μg rhCG + 0.2mg Triptorelin) or GnRH-a trigge...
    Disease:
    Population Age: Adults Gender: Female
    Trial protocol: ES (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2015-001587-19 Sponsor Protocol Number: UHSM0315 Start Date*: 2015-07-15
    Sponsor Name:Manchester University NHS Foundation Trust
    Full Title: A pilot prevention study of the effects of the anti-progestin Ulipristal Acetate (UA) on surrogate markers of breast cancer risk
    Medical condition: We seek to investigate the breast cancer risk reducing properties of ulipristal acetate
    Disease: Version SOC Term Classification Code Term Level
    20.1 10022891 - Investigations 10004746 Biopsy breast normal PT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10006187 Breast cancer PT
    20.0 10022891 - Investigations 10071224 Breast scan PT
    Population Age: Adults Gender: Female
    Trial protocol: GB (GB - no longer in EU/EEA)
    Trial results: (No results available)
    EudraCT Number: 2019-001235-31 Sponsor Protocol Number: DEALSZ-2019-001 Start Date*: 2019-11-26
    Sponsor Name:Charité – Universitätsmedizin Berlin
    Full Title: Factor XII-associated cold autoinflammatory syndrome (FACAS) linked to kallikrein-kinin pathology: Proof of concept treatment with Lanadelumab (DX-2930)
    Medical condition: Lanadelumab in patients with Factor XII-associated cold autoinflammatory syndrome (FACAS)
    Disease: Version SOC Term Classification Code Term Level
    20.0 10021428 - Immune system disorders 10072220 Autoinflammatory disease PT
    Population Age: Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2019-001289-14 Sponsor Protocol Number: MIT-Do001-C301 Start Date*: 2020-02-05
    Sponsor Name:Estetra SRL
    Full Title: A Randomized Double-blind Placebo Controlled Phase 3 Trial to evaluate the Efficacy and Safety of Estetrol for the Treatment of Moderate to Severe Vasomotor Symptoms in Postmenopausal Women (E4Comf...
    Medical condition: Moderate to Severe Vasomotor Symptoms (VMS) in Postmenopausal Women
    Disease: Version SOC Term Classification Code Term Level
    21.0 10047065 - Vascular disorders 10020407 Hot flashes LLT
    Population Age: Adults Gender: Female
    Trial protocol: PL (Completed) GB (GB - no longer in EU/EEA) SK (Completed) HU (Completed) LT (Ongoing) CZ (Completed) ES (Ongoing) IT (Ongoing) RO (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2009-016950-42 Sponsor Protocol Number: 0913M0621 Start Date*: 2010-06-15
    Sponsor Name:Shionogi USA, Inc.
    Full Title: A multicenter, randomized, double-blind, placebo-controlled, parallel-group study to investigate the efficacy and safety of S-888711 tablets administered once-daily for 42 days to adult subjects wi...
    Medical condition: Relapsed persistent or chronic immune thrombocytopenia with or without prior splenectomy.
    Disease: Version SOC Term Classification Code Term Level
    12.1 10066667 Chronic thrombocytopenia LLT
    12.1 10063129 Persisting thrombocytopenia LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Completed) DE (Prematurely Ended) HU (Completed) GB (Prematurely Ended) IT (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2013-003980-74 Sponsor Protocol Number: BAY1007626/15731 Start Date*: 2015-06-17
    Sponsor Name:Bayer AG
    Full Title: Multi-center, randomized, comparator-controlled, single-blind, parallel-group study to investigate the pharmacodynamics, pharmacokinetics and safety of an intrauterine system releasing BAY 1007626,...
    Medical condition: Contraception
    Disease: Version SOC Term Classification Code Term Level
    19.0 100000004865 10010809 Contraception NOS LLT
    Population Age: Adults Gender: Female
    Trial protocol: DE (Completed) GB (Prematurely Ended) NL (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2004-004743-22 Sponsor Protocol Number: FFR30006 Start Date*: Information not available in EudraCT
    Sponsor Name:GlaxoSmithKline Research & Development Ltd
    Full Title: A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Multicenter Study to Evaluate the Efficacy and Safety of Once-Daily, Intranasal Administration of GW685698X Aqueous Nasal Spray 100mc...
    Medical condition: Vasomotor/Idiopathic Rhinitis
    Disease:
    Population Age: Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: NO (Completed) CZ (Completed) DE (Completed)
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    1  2  3  4  5  6  7  8  9  Next» Last»»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Mon May 20 00:20:47 CEST 2024 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA